Evolent Health — Third Quarter 2026 Earnings Summary

Evolent Health reported revenue of $725.4 million for the third quarter of 2026, representing a significant increase from the $479.5 million recorded in the same period of 2025. The company posted a net loss attributable to common shareholders of $23.6 million for the quarter, while adjusted EBITDA reached $34.3 million with a margin of 4.7%. Evolent announced one renewal and two new revenue agreements, including an expansion of oncology services across multiple states, bringing the year-to-date total of new agreements to seven. Looking ahead, the company reiterated its full-year 2026 revenue guidance of $2.6 billion to $2.7 billion and raised its adjusted EBITDA guidance range to $130.0 million to $135.0 million.